
-
ADMA Biologics NasdaqGM:ADMA ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Location: 465 State Route 17, Ramsey, NJ, 07446, United States | Website: https://www.admabiologics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
4.747B
Cash
71.63M
Avg Qtr Burn
N/A
Short % of Float
5.70%
Insider Ownership
2.59%
Institutional Own.
88.40%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
BIVIGAM® Details Autoimmune disease, Immunodeficiency, Primary humoral immunodeficiency | Approved Quarterly sales | |
ASCENIV™ Details Immunodeficiency, Autoimmune disease, Primary humoral immunodeficiency | Approved Quarterly sales | |
Nabi-HB® Details Hepatitis B | Approved Quarterly sales |